论文部分内容阅读
目的：为探讨抑癌基因Ｐ１６蛋白在膀胱移行细胞癌中的表达与预后关系。方法：应用免疫组织化学，检测５５例膀胱移行细胞癌Ｐ１６蛋白表达。结果：５５例膀胱移行细胞癌中，Ｐ１６蛋白表达阳性率４１．８％，在膀胱移行细胞癌Ⅰ、Ⅱ、Ⅲ级中分别为６８．８％、３５％、２６．３％，Ｐ１６蛋白表达阳性率随病理分级增高而降低，Ⅰ级与Ⅱ级、Ⅲ级比较有显著性差异（Ｐ＜０．０５）。Ｐ１６蛋白阳性表达患者死亡率８．７％，阴性表达患者死亡率３１．３％，阳性表达者死亡率明显低于阴性表达者，Ｐ１６蛋白表达与预后呈负相关（Ｐ＜０．０５）。结论：我们认为Ｐ１６蛋白检测有助于判断膀胱癌的预后。
Objective: To investigate the relationship between the expression of the tumor suppressor gene P16 and bladder transitional cell carcinoma and its prognosis. Methods: Immunohistochemistry was used to detect the expression of P16 protein in 55 cases of bladder transitional cell carcinoma. Results: The positive rate of P16 protein in 55 cases of bladder transitional cell carcinoma was 41.8%, which was 68.8%, 35%, 26.3% respectively in bladder transitional cell carcinoma Ⅰ, Ⅱ and Ⅲ, P16 protein expression The positive rate decreased with the pathological grade increased, grade Ⅰ and Ⅱ, Ⅲ grade significant difference (P <0.05). The mortality rate of P16 protein positive patients was 8.7%, that of negative patients was 31.3%, and that of positive patients was significantly lower than that of negative ones (P <0.05). CONCLUSIONS: We believe P16 protein testing can help predict the prognosis of bladder cancer.